Mild cognitive impairment

Where the papers sit

12 papers from the last 6 months study mild cognitive impairment directly · updated from PubMed 9 Oct 2026

• Biomarkers of Cognitive Decline

  Alzheimer's disease risk is being framed through multimodal biomarkers and systemic contributors rather than cognition alone. CSF blood-brain barrier dysfunction, hypothalamic structure, brain insulin resistance, and omics signatures recur alongside Montreal Cognitive Assessment and daily-function measures. Time-sensitive models aim to predict progression from mild cognitive impairment, while population cohorts connect findings to ageing and healthy life expectancy. The shared direction is earlier risk stratification, but the biological markers and their predictive value remain under validation.

  6 papers · 50%

• Digital Support for Dementia

  Digital reminders and family-supported interventions are being tested to sustain independence and quality of life in mild cognitive impairment and dementia. SMART4MD uses monitoring and reminders, with controlled-trial outcomes including dropout and quality-adjusted life years. Hearing-aid support extends this behavioral approach to modifiable sensory risk and caregiver involvement. Evidence remains centered on feasibility, adherence, and patient-reported benefit rather than definitive prevention of dementia.

  3 papers · 25%

• Others — Cognitive and Cancer Research

  Lecanemab is being compared with acetylcholinesterase inhibitors in real-world Alzheimer's disease care, with survival and effectiveness as endpoints. EEG-based neural networks address MCI detection and seek biologically interpretable decisions rather than treatment effects. WT1 peptide vaccination concerns post-allogeneic HSCT maintenance in pediatric acute leukemia, not cognitive impairment. These topics share no biological question, so no unified direction or coherent subject emerges.

  3 papers · 25%